J
Jean-Louis Pujol
Researcher at University of Montpellier
Publications - 170
Citations - 8350
Jean-Louis Pujol is an academic researcher from University of Montpellier. The author has contributed to research in topics: Lung cancer & Population. The author has an hindex of 42, co-authored 168 publications receiving 7431 citations. Previous affiliations of Jean-Louis Pujol include French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
Fabrice Barlesi,Julien Mazieres,Jean-Philippe Merlio,Didier Debieuvre,Jean Mosser,Hervé Lena,L'Houcine Ouafik,Benjamin Besse,Isabelle Rouquette,Virginie Westeel,Fabienne Escande,Isabelle Monnet,Antoinette Lemoine,Remi Veillon,Hélène Blons,Clarisse Audigier-Valette,Pierre-Paul Bringuier,R. Lamy,Michèle Beau-Faller,Jean-Louis Pujol,Jean-Christophe Sabourin,Frédérique Penault-Llorca,Marc G. Denis,Sylvie Lantuejoul,Franck Morin,Quân Tran,P. Missy,Alexandra Langlais,Bernard Milleron,Jacques Cadranel,Jean-Charles Soria,Gérard Zalcman +31 more
TL;DR: The frequency of genetic alterations, acceptable turnaround times in obtaining analysis results, and the clinical advantage provided by detection of a genetic alteration suggest that this nationwide molecular profiling of patients with advanced NSCLC provides a clinical benefit.
Journal ArticleDOI
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
Luis Paz-Ares,Filippo de Marinis,Mircea Dediu,Michael Thomas,Jean-Louis Pujol,Paolo Bidoli,Olivier Molinier,Tarini Prasad Sahoo,E. Laack,Martin Reck,Jesus Corral,Symantha Melemed,William J. John,Nadia Chouaki,Annamaria Zimmermann,Carla Visseren-Grul,Cesare Gridelli +16 more
TL;DR: There was a significant reduction in the risk of disease progression over the placebo group, and the primary endpoint was progression-free survival in the intention-to-treat population.
Journal ArticleDOI
PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer
Luis Paz-Ares,Filippo de Marinis,Mircea Dediu,Mike Thomas,Jean-Louis Pujol,Paolo Bidoli,Olivier Molinier,Tarini Prasad Sahoo,Eckart Laack,Martin Reck,Jesus Corral,Symantha Melemed,William J. John,Nadia Chouaki,Annamaria Zimmermann,Carla Visseren-Grul,Cesare Gridelli +16 more
TL;DR: Pemetrexed continuation maintenance therapy is well-tolerated and offers superior OS compared with placebo, further demonstrating that it is an efficacious treatment strategy for patients with advanced nonsquamous NSCLC and good performance status who did not progress during pemetrexing-cisplatin induction therapy.
Journal ArticleDOI
Survival of Patients With Resected N2 Non–Small-Cell Lung Cancer: Evidence for a Subclassification and Implications
Fabrice Andre,Dominique Grunenwald,Jean-Pierre Pignon,Antoine Dujon,Jean-Louis Pujol,Pierre Yves Brichon,Laurent Brouchet,Elisabeth Quoix,Virginie Westeel,Thierry Le Chevalier +9 more
TL;DR: This study has identified homogeneous N2 NSCLC prognostic subgroups and suggests different therapeutic approaches according to the subgroup profile.
Journal ArticleDOI
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kazuhiko Nakagawa,Edward B Garon,Takashi Seto,Makoto Nishio,Santiago Ponce Aix,Luis Paz-Ares,Chao-Hua Chiu,Keunchil Park,Silvia Novello,Ernest Nadal,Fumio Imamura,Kiyotaka Yoh,Jin-Yuan Shih,Kwok Hung Au,Denis Moro-Sibilot,Sotaro Enatsu,Annamaria Zimmermann,Bente Frimodt-Moller,Carla Visseren-Grul,Martin Reck,Quincy Chu,Alexis B. Cortot,Jean-Louis Pujol,Elizabeth Fabre,Corinne Lamour,Helge Bischoff,Jens Kollmeier,M Kimmich,Walburga Engel-Riedel,Stefan Hammerschmidt,Wolfgang Schütte,Konstantinos N. Syrigos,James Chung-Man Ho,Kwok-Hung Au,Andrea Ardizzoni,Giulia Pasello,Vanessa Gregorc,Alessandro Del Conte,Domenico Galetta,Toshiaki Takahashi,Toru Kumagai,Katsuyuki Hotta,Yasushi Goto,Yukio Hosomi,Hiroshi Sakai,Yuichi Takiguchi,Young Hak Kim,Takayasu Kurata,Hiroyuki Yamaguchi,Haruko Daga,Isamu Okamoto,Miyako Satouchi,Satoshi Ikeda,Kazuo Kasahara,Shinji Atagi,Koichi Azuma,Keisuke Aoe,Yoshitsugu Horio,Nobuyuki Yamamoto,Hiroshi Tanaka,Satoshi Watanabe,Naoyuki Nogami,Tomohiro Ozaki,Ryo Koyama,Tomonori Hirashima,Hiroyasu Kaneda,Keisuke Tomii,Yuka Fujita,Masahiro Seike,Naoki Nishimura,Terufumi Kato,Masao Ichiki,Hideo Saka,Katsuya Hirano,Yasuharu Nakahara,Shunichi Sugawara,Sang-We Kim,Young Joo Min,Hyun Woo Lee,Jin-Hyoung Kang,Ho Jung An,Ki Hyeong Lee,Jin Soo Kim,Gyeong-Won Lee,Sung Yong Lee,A. Alexandru,Anghel Adrian Udrea,Óscar Juan-Vidal,Ernest Nadal-Alforja,Ignacio Gil-Bazo,Santiago Ponce-Aix,Belén Rubio-Viqueira,Miriam Alonso Garcia,Enriqueta Felip Font,Jose Fuentes Pradera,Juan Coves Sarto,Meng-Chih Lin,Wu Chou Su,Te Chun Hsia,Gee-Chen Chang,Yu-Feng Wei,Jian Su,Irfan Cicin,Tuncay Göksel,Hakan Harputluoglu,Ozgur Ozyilkan,Ivo Henning,Sanjay Popat,Olivia Hatcher,Kathryn Mileham,Jared Acoba,Edward B. Garon,Gabriel Jung,Moses Sundar Raj,William J. Martin,Shaker R. Dakhil +115 more
TL;DR: The RELAY trial as mentioned in this paper evaluated erlotinib, an EGFR tyrosine kinase inhibitor (TKI) standard of care, plus ramucirumab, a human IgG1 VEGFR2 antagonist, or placebo in patients with untreated EGFR-mutated metastatic NSCLC.